Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 0.94B P/E 8.73 EPS this Y -190.20% Ern Qtrly Grth -
Income 96.55M Forward P/E -10.47 EPS next Y 8.70% 50D Avg Chg -5.00%
Sales 243.69M PEG - EPS past 5Y - 200D Avg Chg 11.00%
Dividend N/A Price/Book 1.99 EPS next 5Y - 52W High Chg -20.00%
Recommedations 2.90 Quick Ratio 9.01 Shares Outstanding 106.57M 52W Low Chg 59.00%
Insider Own 14.98% ROA 16.77% Shares Float 87.47M Beta 0.00
Inst Own 48.91% ROE 26.33% Shares Shorted/Prior 3M/3.67M Price 8.90
Gross Margin 100.00% Profit Margin 39.62% Avg. Volume 716,206 Target Price 12.50
Oper. Margin -1,061.87% Earnings Date Mar 22 Volume 229,448 Change -1.44%
About POINT Biopharma Global Inc.

POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana. As of December 27, 2023, POINT Biopharma Global Inc. operates as a subsidiary of Eli Lilly and Company.

PNT Chatroom

User Image newsfile_corp Posted - 4 months ago

https://nfne.ws/216454 $PNT #Banking #FinancialServices #NASDAQ #Investing

User Image GwilliamG Posted - 6 months ago

@FonsieTrader - objectively speaking, this is a grossly undervalued company as compared to it's peers....and the space is HOT! -- $FUSN, $PNT, $CATX, mariana With a late stage asset (Iomab-B) that had knockout Ph3 results it appears to be more of a valuation stand-off between BP and ATNM. I think a well negotiated CVR gets this over the finish line in '24. I'll invite @resume777 , @Karmic to add their take on this as well

User Image JG101 Posted - 8 months ago

$ATNM I presume many like me who owned both $ATNM and $FUSN and who made a killing on $FUSN are now doubling down into $ATNM. Also a bunch of people who knew little to nothing of RadioPharma are now fully awake after $PNT, $RYZB and now $FUSN were bought out for impressive premiums. At 200 million of market cap acquiring a sizeable position will need a lot of small shareholders to sell to the big fish. This company is extraordinarily cheap by any metric.

User Image joka2189 Posted - 8 months ago

$PNT $RYZB $PSTV $FUSN $NBTX another one bites the dust. Bye Fusionđź‘‹

User Image AAVIE Posted - 9 months ago

@resume777 what happened to the $LLY and $PNT acquisition? cant read pickerbefores posts

User Image resume777 Posted - 9 months ago

@Pickerbefore that's what happened with the $LLY and $PNT acquisition.

User Image perchedcats Posted - 9 months ago

$CATX seems that PB is best radioisotope - this was also confirmed when $PNT (just $LLY before BO was announced signed a strategic supply deal for PB… so $catx is leading with this tech… while most others are using Actinium

User Image techj2022 Posted - 9 months ago

$FUSN relative strength vs xbi today. other radio pharmas $PNT $RYZB $CLRB $PSTV

User Image JenineKeyt134 Posted - 01/30/24

$PNT Rising uranium markets are shedding light on STLNF's resource-rich projects.

User Image VirginiaUber751 Posted - 01/22/24

$PNT Rising uranium markets are shedding light on STLNF's resource-rich projects.

User Image knowthyself Posted - 10 months ago

$LNTH $PNT Might not be the last word on PNT 2002. "Importantly, participants in the control arm could “cross over” to receive PNT2002 if their disease progressed. Some 84% of those who experienced progression ended up doing so, potentially confounding the study’s survival results. At the time of the analysis, survival results favored the control arm, but the picture could change as more data are accrued as the study continues. Point said additional results are expected next year. A similar pattern happened in Novartis’ study of Pluvicto, which showed treatment led to a median progression-free survival of 12 months, but no survival benefit. For Lilly, the SPLASH results may be beside the point.... Their interest in Point had equally as much to do with the company’s manufacturing and research capabilities. “Our interest in Point is a lot around the platform,” said Lilly’s CMO. “I think the time is right to get into therapeutic radiopharmaceuticals.”

User Image knowthyself Posted - 10 months ago

$LNTH $PNT Anyone have a good read on the PNT 2002 trial? Hit the primary endpoint, but came up short on the secondary--overall survival. In the press result, it said data was was not mature, only 49% of patients available. Any thoughts? Will OS improve? And if it doesn't, is the drug a dud? Has one hell of a TAM, if it is successful, in the billions.

User Image ChartLaboratory_com Posted - 10 months ago

$PNT testing vwap,> can be a monster heerover 4.70

User Image CryptoAtlas Posted - 10 months ago

$PGY $LCTX $MCRB $PNT Current spec positions...I don't consider STNE a spec anymore. It's a solid growth value play.

User Image joka2189 Posted - 10 months ago

$PNT $RYZB very hot space surprise surprise as another one for solids gets absorbed. Not too many go-it alones left in the 'race'! Big $PSTV Plus Point! $FUSN or $NBTX likely next ones to go. Horses for courses.

User Image risenhoover Posted - 10 months ago

$PNT / POINT Biopharma Global files form 15-12G https://fintel.io/doc/sec-point-biopharma-global-inc-1811764-1512g-2024-january-08-19730-6502?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

User Image Stock_Titan Posted - 10 months ago

$PNT Domain Therapeutics Strengthens Leadership Team to Spearhead Global Development and North American Expansion as the Leading GPCR Immuno-Oncology Company https://www.stocktitan.net/news/PNT/domain-therapeutics-strengthens-leadership-team-to-spearhead-global-r3um2u9wzpdk.html

User Image UncleStock Posted - 10 months ago

$SMLR $PNT $EGRX $VNDA suggested for Health Care - value screen: https://zpr.io/w3j8HS7Eft4n

User Image tickeron Posted - 12/31/23

If you are an active trader, pay attention! $PNT in -11.27% Downtrend, declining for three consecutive days on December 19, 2023. View odds for this and other indicators: https://srnk.us/go/4956163

User Image UncleStock Posted - 12/29/23

$PNT $EGRX $VNDA $INVA suggested for Pharmaceuticals and Biotechnology - value screen: https://zpr.io/NGP6QnBCdEbN

User Image MWM Posted - 12/28/23

$FUSN last man standing after $PNT and $RYZB?

User Image josephfuller Posted - 12/27/23

$PNT CATX People!. Their Pipe Is As Good As RAYZE Bio People!.

User Image chunkynuts Posted - 12/27/23

$PNT did this get bought out? And at what price

User Image Ah121 Posted - 12/27/23

$PNT will the stock be up next year ?

User Image Screaming_Eagle Posted - 12/27/23

$PNT F you Ari. Hope you ch0ke on that money. Only reason why you're there was because of your uncle Allan S

User Image risenhoover Posted - 12/27/23

$PNT / POINT Biopharma Global files form S-8 POS https://fintel.io/doc/sec-point-biopharma-global-inc-1811764-s8-pos-2023-december-27-19718-1309?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

User Image risenhoover Posted - 12/27/23

$PNT / POINT Biopharma Global files form S-8 POS https://fintel.io/doc/sec-point-biopharma-global-inc-1811764-s8-pos-2023-december-27-19718-6963?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

User Image risenhoover Posted - 12/27/23

$PNT / POINT Biopharma Global files form S-8 POS https://fintel.io/doc/sec-point-biopharma-global-inc-1811764-s8-pos-2023-december-27-19718-6895?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

User Image Last10K Posted - 12/27/23

$PNT just filed with the SEC a Ending Agreement, a Change in Assets, a Listing Status, a Security Holders Change, a Change in Control, a Event for Officers, a Bylaw Change and a Financial Exhibit https://last10k.com/sec-filings/PNT/0001193125-23-303512.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=PNT

User Image risenhoover Posted - 12/27/23

$PNT / POINT Biopharma Global files form 8-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 POINT BIOPHARMA https://fintel.io/doc/sec-point-biopharma-global-inc-1811764-8k-2023-december-27-19718-8776?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

Analyst Ratings
Brookline Capital Hold Dec 21, 23
Piper Sandler Neutral Oct 24, 23
Raymond James Market Perform Oct 6, 23
Truist Securities Hold Oct 4, 23
JonesTrading Hold Oct 4, 23
Oppenheimer Outperform May 16, 23
Raymond James Outperform Dec 14, 22
SVB Leerink Outperform Nov 30, 22
Truist Securities Buy Nov 15, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
BVF PARTNERS L P/IL - - Dec 18 Sell 12.45 17,161,278 213,657,911 12/20/23
HOGUE GERALD L. Director Director Mar 21 Option 6.97 17,936 125,014 21,596 03/23/23
MCCANN JOE A. Chief Executive Offi.. Chief Executive Officer Nov 29 Buy 6.64 2,160 14,342 3,616,313 11/30/22
MARGOLIN YAEL Director Director Nov 21 Buy 6.56 1,710 11,218 1,710 11/23/22